Anlotinib in combination with temozolomide dose-dense regimen in patients with recurrent high-grade glioma
Objective To analyze the efficacy and safety of combining anlotinib with temozolomide dose-dense regimen for recurrent high-grade glioma.Methods The clinical data of 42 patients who had recurrent high-grade glioma and were treated with the combined therapy of anlotinib and temozolomide dose-dense regimen at the First Affiliated Hospital of Ningbo University from January 2018 to Feb-ruary 2023 were collected.The short-term effect,survival,and adverse events were assessed.Results Among the 42 patients with recur-rent high-grade glioma,26 cases were World Health Organization(WHO)grade 4,and 16 cases were WHO grade 3.The objective response rate was 38.1%,and the disease control rate reached 81.0%.The median progression free survival(PFS)was 5.2 months,and the 6-month PFS rate was 38.1%.The median overall survival(OS)was 8.6 months,and the 12-month OS rate was 14.3%.Among the most frequently reported treatment-related adverse events were hand-foot skin reaction,hypertension,marrow suppression,and gastrointestinal reactions.All treatment-related adverse events were grade 1 or 2.Conclusions Combining anlotinib with temozolomide dose-dense regimen has promising efficacy and well-tolerated adverse events in patients with recurrent high-grade glioma.
万方数据
维普
